Tarsus Pharmaceuticals Inc (TARS)
R&D Expense Growth
38.74%
Quarterly · Period ending:
TARS R&D Expense Growth
Latest reported38.74%period ending
Latest reported38.74%period ending
TARS Quarterly R&D Growth (QoQ) (0.00% → 38.74%)
Latest values, visible window
High-resolution chart · PNG
TARS r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 38.741% | |
| 23.9312% | |
| 10.7529% | |
| 4.4248% | |
| 8.224% | |
| -14.6032% | |
| 39.1243% | |
| -1.5505% | |
| 2.0968% | |
| -9.3123% | |
| 9.9133% | |
| -3.5151% | |
| 1.5377% | |
| 23.215% | |
| -8.1012% | |
| 13.6312% | |
| -20.5115% | |
| 50.2986% | |
| -21.2656% | |
| 41.7129% | |
| -55.6977% | |
| 114.3271% | |
| -5.0557% | |
| 360.0461% | |
| 14.881% | |
| 116.9297% | |
| 74.6867% | |
| 0% | |
| 0% | |
| 0% |